US Stock Market Move | The Phase 1 trial of WVE-007 produced positive results, causing Wave Life Sciences (WVE.US) to soar nearly 80% at the opening.

On Monday, Wave Life Sciences (WVE.US) surged nearly 80% at the opening, hitting a new high for the year at $13.42. The company announced that the interim data from the phase 1 trial of WVE-007 for treating obesity showed improvements in body composition. At the lowest treatment dose, the weight loss effect was similar to GLP-1, but without muscle loss. Research showed that a single dose of 240mg of WVE-007 reduced visceral fat by 9.4%, total body fat by 4.5%, and increased lean body weight by 3.2%. Wave Life Sciences also stated that the interim data further indicated that WVE-007 was generally safe and well-tolerated, with only mild treatment-related adverse events. Further clinical data updates, including six-month follow-up data for the 240mg single dose group, are expected to be released in the first quarter of 2026.